Abstract
The calcimimetic cinacalcet is now being used for years to treat secondary hyperparathyroidism (SHPT) in dialysis patients, allowing a good reduction in PTH levels. In order to evaluate a possible beneficial effect on cardiovascular prognosis, a randomized trial, the EVOLVE (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events), was conducted in 3,883 dialysis patients affected by moderate to severe SHPT.Patients were randomly assigned to receive cinacalcet or placebo. The primary composite endpoint evaluated was time until death, myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular events. Due to a low statistical power, there was no significant difference between the two arms of the study in the intention-to-treat analysis, despite a higher incidence of hypocalcaemia, nausea, and vomiting in patients treated with cinacalcet.The results of the EVOLVE study have certainly disappointed the nephrological community that would have expected ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
